NORTHERA(TM) Clinical Trial Data Published in Neurology
19. Juni 2014 16:30 ET
|
Chelsea Therapeutics
CHARLOTTE, N.C., June 19, 2014 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced the publication in Neurology of its pivotal, Phase 3 study 301, a multicenter,...
Chelsea Therapeutics Presents Efficacy and Safety Data for NORTHERA at International Congress of Parkinson's Disease and Movement Disorders
12. Juni 2014 07:30 ET
|
Chelsea Therapeutics
-First Presentation of Integrated Data Analyses From Two Pivotal Trials
-Data Shows Statistically Significant Improvement in Symptoms of NOH vs. Placebo
CHARLOTTE, N.C. and STOCKHOLM, Sweden,...
Chelsea Therapeutics Announces the Expiration of the Hart-Scott-Rodino Waiting Period in Relation to the Proposed Acquisition of Chelsea Therapeutics by Lundbeck
06. Juni 2014 07:00 ET
|
Chelsea Therapeutics
CHARLOTTE, N.C., June 6, 2014 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust...
Chelsea Therapeutics to Host Conference Call to Discuss Acquisition by Lundbeck
08. Mai 2014 07:58 ET
|
Chelsea Therapeutics
CHARLOTTE, N.C., May 8, 2014 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Chelsea) (Nasdaq:CHTP), a biopharmaceutical development company, has entered into a definitive agreement to...
Lundbeck to Acquire Chelsea Therapeutics
08. Mai 2014 07:54 ET
|
Chelsea Therapeutics
By acquiring Chelsea Therapeutics, Lundbeck gains the rights to Chelsea Therapeutics' recently FDA-approved product, NORTHERATM (droxidopa), which is expected to be launched later in 2014...
Chelsea Therapeutics Reports Fourth Quarter and Full-Year 2013 Results
11. März 2014 16:25 ET
|
Chelsea Therapeutics
CHARLOTTE, N.C., March 11, 2014 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today reported financial results for the fourth quarter and full year ended December 31,...
Chelsea Therapeutics Joins NORD in Promoting Awareness for Rare Disease Day
28. Februar 2014 07:00 ET
|
Chelsea Therapeutics
CHARLOTTE, N.C., Feb. 28, 2014 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP), which recently received Food and Drug Administration (FDA) accelerated approval of NORTHERATM...
Chelsea Therapeutics Issues Statement Regarding Postponement of NORTHERA(TM) (Droxidopa) NDA PDUFA Action Date Due to Severe Weather
14. Februar 2014 18:55 ET
|
Chelsea Therapeutics
CHARLOTTE, N.C., Feb. 14, 2014 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today issued the following statement regarding the U.S. Food and Drug Administration (FDA)...
Chelsea Therapeutics Names Keith W. Schmidt Chief Commercial Officer
30. Januar 2014 07:00 ET
|
Chelsea Therapeutics
CHARLOTTE, N.C., Jan. 30, 2014 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced that Keith W. Schmidt has been named Chief Commercial Officer, effective...
Chelsea Therapeutics Announces Joseph G. Oliveto Named President and Chief Executive Officer, Director
27. Januar 2014 07:00 ET
|
Chelsea Therapeutics
CHARLOTTE, N.C., Jan. 27, 2014 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced that Joseph G. Oliveto has been named President and Chief Executive Officer...